Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer-Reference-Cited by-同舟云学术

Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer

Published:2016-04-12 Issue:10 Volume:43 Page:1792-1801
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Woff Erwin,Hendlisz Alain,Garcia Camilo,Deleporte Amelie,Delaunoit Thierry,Maréchal Raphaël,Holbrechts Stéphane,Van den Eynde Marc,Demolin Gauthier,Vierasu Irina,Lhommel Renaud,Gauthier Namur,Guiot Thomas,Ameye Lieveke,Flamen Patrick

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-016-3365-x.pdf

Reference38 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014;136:359–86.

2. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–12.

3. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, et al. Regorafenib (BAY 73–4506) in advanced colorectal cancer: a phase I study. Br J Cancer. 2012;106:1722–7.

4. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, et al. A phase I dose–escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18:2658–67.

5. Van den Abbeele AD. The lessons of GIST--PET and PET/CT: a new paradigm for imaging. Oncologist. 2008;13:8–13.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Response heterogeneity as a new biomarker of treatment response in patients with neuroendocrine tumors;Future Oncology;2023-10

2. Tailoring the clinical management of colorectal cancer by 18F-FDG PET/CT;Frontiers in Oncology;2022-12-22

3. Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer;Journal of Nuclear Medicine;2021-07-29

4. PET/CT in the Assessment of Treatment Response in Hepatobiliary, Gall Bladder and Pancreatic Malignancies;Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology;2021

5. Positron Emission Tomography/Computed Tomography in Colorectal Cancer;Applications of FDG PET in Oncology;2020-12-08